Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 305

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 305
---
 benefits are realized. •Workforce Reductions; Layoffs or restructuring may lead to dissatisfaction, legal challenges, and negative publicity. •System Integration Risks: IT system failures, cybersecurity vulnerabilities, or data migration errors could disrupt operations. 134 Competitive Considerations •Advantages •Enhanced Market Positioning: The Merger strengthens the perceived value and credibility of the combined company, attracting investors and strategic partners. •Increased Innovation Potential: By combining R&D efforts and intellectual property, the combined company may accelerate the development of breakthrough solutions. •Improved Fundraising Leverage: A larger, combined company may have greater appeal to investors, securing funding at better terms. •Risks •Unclear Market Fit: Without already established scientific rationale, proving product -marketfit post -Mergermay be challenging. •Investor Uncertainty: Merging two early -stagecompanies may raise concerns about execution risks and financial sustainability, making fundraising more difficult. •Integration Disruptions: Combining teams, research pipelines, and strategic visions could slow down product development and delay time -to-market. Shareholder Considerations •Advantages •Increased Value: The Merger is anticipated to enhance financial performance and potentially increase returns for shareholders through several key avenues: •Diversified and Advanced Product Pipeline: By combining their resources, the combined company will boast a robust portfolio targeting significant medical needs. NLS contributes its Dual Orexin Receptor Agonist platform, focusing on treatments for sleep disorders and neurodegenerative diseases. Kadimastem adds its cell therapy products, including AstroRx® for ALS and IsletRx for diabetes. This diversified pipeline enhances the potential for successful product development and subsequent revenue generation. •Enhanced Market Presence and Access to Capital: The Merger is structured to result in a larger Nasdaq -tradedbiotechnology company, increasing visibility and credibility in the U.S. capital markets. This enhanced market presence is expected to facilitate better access to funding opportunities, supporting ongoing and future research and development initiatives. •Operational and Financial Synergies: The consolidation of NLS’s and Kadimastem’s operations is expected to yield cost efficiencies through streamlined processes and reduced overhead. These synergies can improve operational efficiency and financial performance, potentially leading to enhanced earnings. •Strategic Focus and Asset Optimization: Post -Merger, the combined company plans to focus on advancing Kadimastem’s cell therapy platform while continuing the development of NLS’s DOXA program. Additionally, NLS’s legacy assets, including mazindol, are expected to